Metabolic profile correction in patients with type 2 diabetes mellitus, suffering from obesity, with antidiabetic drug with active component based on the antibodies to C-terminal fragment of the β-subunit of the insulin receptor
Abstract
The world health organization calls obesity and type 2 diabetes mellitus a delayed disaster. There is a significant relationship between diabetes mellitus and the risk of cardiovascular events, cancer and cognitive impairment. Insulin resistance is considered one of the key links in the development of these diseases. For this reason, modern antidiabetic drugs should not only solve the problem of normalization of carbohydrate metabolism parameters, but also have pleiotropic properties, affecting the pathogenesis. This article discusses the therapeutic effect of technologically processed antibodies to the C-terminal fragment of the β-subunit of the insulin receptor in the treatment of patients with type 2 diabetes mellitus and obesity.
About the Authors
N. V. Rogova
ФГБОУ ВО ВолгГМУ Минздрава России
Russian Federation
Russian Federation
A. Yu. Ryazanova
ФГБОУ ВО ВолгГМУ Минздрава России
Russian Federation
Russian Federation
References
1. Zheng Y., Ley S. H., Hu F. B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications // Nat Rev Endocrinol. 2018, Feb; 14 (2): 88-98.
2. WHO: Obesity and Overweight. Fact sheet No. 311. 2016. www.who.int/mediacentre/factsheets/fs311/en/ (доступно на 28.06.2019).
3. Prospective Studies Collaboration, Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., Qizilbash N., Collins R., Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies // Lancet. 2009; 373: 1083-1096.
4. Fried M., Yumuk V., Oppert J. M., Scopinaro N., Torres A. J., Weiner R., Yashkov Y., Fruhbeck G. European Association for the Study of Obesity, International Federation for the Surgery of Obesity - European Chapter: Interdisciplinary European guidelines on metabolic and bariatric surgery // Obes Facts. 2013; 6: 449-468.
5. International Diabetes Federation: Diabetes Atlas, 2nd ed. Brussels, International Diabetes Federation, 2003. www.diabetesatlas.org/component/attachments/?task=download&id=73 (доступно на 28.06.2019).
6. Hossain P., Kawar B., El Nahas M. Obesity and diabetes in the developing world - a growing challenge // N Engl J Med. 2007; 356: 213-215.
7. Oldridge N. B., Stump T. E., Nothwehr F. K., Clark D. O. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults // J Clin Epidemiol. 2001; 54: 928-934.
8. Boucher J., Kleinridders A., Kahn R. C. Insulin Receptor Signaling in Normal and Insulin-Resistant // States Cold Spring Harb Perspect Biol. 2014; 6: a009191.
9. Bays H., Mandarino L., DeFronzo R. A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach // J Clin Endocrinol Metab. 2004, Feb; 89 (2): 463-478.
10. Granberry M. C., Fonseca V. A. Insulin resistance syndrome: options for treatment // South Med J. 1999, Jan; 92 (1): 2-15.
11. Kasuga M., Karlsson F. A., Kahn C. R. Insulin stimulates the phosphorylation of the 95,000-Dalton subunit of its own receptor // Science. 1982, Feb, 215 (4529): 185-187.
12. Gual P., Baron R., Alengrin F., Mothe I., Obberghen E. Insulin Receptor-Induced Phosphorylation of Cellular and Synthetic Substrates Is Regulated bythe Receptor P-Subunit C-Terminus // Endocrinology. 1996. Vol. 137. P. 3416-3423.
13. Paz K., Voliovitch H., Hadari Y. R., Roberts C. T., LeRoith J. D., Zick Y. Interaction between the Insulin Receptor and Its Downstream Effectors // Journal of Biological Chemistry. 1996. Vol. 271. P. 6998-7003.
14. Sykiotis G. P., Papavassiliou A. G. Serine Phosphorylation of Insulin Receptor Substrate-1: A Novel Target for the Reversal of Insulin Resistance // Molecular Endocrinology. 2001. Vol. 15 (11). P. 1864-1869.
15. Paz K., Hemi R., LeRoith D., Karasik A., Elhananyi E., Kanety H., Zick Y. A Molecular Basis for Insulin Resistance // Journal of Biological Chemistry. 1997. Vol. 272. P. 29911-29918.
16. Adel S. Al-Zubairi, Eltayeb Elamin M. Molecular Targets in the Development of Antidiabetic Drugs // International Journal of Pharmacology. 2010, 6: 784-795.
17. Vaz J. A., Patnaik A. Diabetes mellitus: Exploring the challenges in the drug development process // Perspect Clin Res. 2012; 3 (3): 109-112.
18. Bornfeldt K. E., Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis // Cell Metab. 2011; 14 (5): 575-585.
19. Orgel E., Mittelman S. D. The links between insulin resistance, diabetes, and cancer // Curr Diab Rep. 2013; 13 (2): 213-222.
20. Jia G., DeMarco V. G., Sowers J. R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy // Nat Rev Endocrinol. 2016; 12 (3): 144-153.
21. Joost H. G., Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review) // Mol Membr Biol. 2001; 18 (4): 247-256.
22. Горбунов Е. А., Nicoll J., Мысливец А. А. и др. Субетта повышает чувствительность мышечных клеток человека к инсулину // Бюллетень экспериментальной биологии и медицины. 2015; 159 (4): 454-456.
23. Yazici D., Sezer H. Insulin Resistance, Obesity and Lipotoxicity // Adv Exp Med Biol. 2017; 960: 277-304.
24. Nicoll J., Gorbunov E. A., Tarasov S. A., Epstein O. I. Subetta Treatment Increases Adiponectin Secretion by Mature Human Adipocytes In Vitro // International Journal of Endocrinology. 2013: 925874. Published online 2013, Apr 18.
25. Gorbunov E. А., Nicoll J., Kachaeva E. V., Tarasov S. А., Epstein О. I. Subetta increases phosphorylation of insulin receptor ?-subunit alone and in the presence of insulin // Nutrition & Diabetes. 2015. Vol. 5 (7). P. 169.
26. Инструкция по медицинскому применению препарата Субетта. ЛСР - 007376/10 grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid= 83f9a6c1-1115-41a2-b329-440652c7954e&t. Доступно на 28.06.2019.
Review
For citations:
Rogova N.V., Ryazanova A.Yu. Metabolic profile correction in patients with type 2 diabetes mellitus, suffering from obesity, with antidiabetic drug with active component based on the antibodies to C-terminal fragment of the β-subunit of the insulin receptor. Lechaschi Vrach. 2019;(8):72. (In Russ.)
Views:
244
JATS XML
Email this article 
